These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10655005)

  • 1. Shorter hospital stays and more rapid improvement among patients with schizophrenia and substance disorders.
    Ries RK; Russo J; Wingerson D; Snowden M; Comtois KA; Srebnik D; Roy-Byrne P
    Psychiatr Serv; 2000 Feb; 51(2):210-5. PubMed ID: 10655005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychiatric Hospitalizations of Chronic Psychotic Disorder Patients With and Without Dual Diagnosis, Israel, 1963-2016.
    Florentin S; Rosca P; Raskin S; Bdolah-Abram T; Neumark Y
    J Dual Diagn; 2019; 15(3):130-139. PubMed ID: 31079564
    [No Abstract]   [Full Text] [Related]  

  • 3. Diagnosis and management of substance use disorders among inpatients with schizophrenia.
    Kirchner JE; Owen RR; Nordquist C; Fischer EP
    Psychiatr Serv; 1998 Jan; 49(1):82-5. PubMed ID: 9444685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost of treating substance abuse patients with and without comorbid psychiatric disorders.
    Hoff RA; Rosenheck RA
    Psychiatr Serv; 1999 Oct; 50(10):1309-15. PubMed ID: 10506299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of neighborhood environment on treatment continuity and rehospitalization in dually diagnosed patients discharged from acute inpatient care.
    Stahler GJ; Mennis J; Cotlar R; Baron DA
    Am J Psychiatry; 2009 Nov; 166(11):1258-68. PubMed ID: 19797433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting clinically significant change in an inpatient program for people with severe mental illness.
    Gonda T; Deane FP; Murugesan G
    Aust N Z J Psychiatry; 2012 Jul; 46(7):651-8. PubMed ID: 22528976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders.
    Barrowclough C; Haddock G; Tarrier N; Lewis SW; Moring J; O'Brien R; Schofield N; McGovern J
    Am J Psychiatry; 2001 Oct; 158(10):1706-13. PubMed ID: 11579006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Awareness of substance abuse problems among dually-diagnosed psychiatric inpatients.
    RachBeisel J; Dixon L; Gearon J
    J Psychoactive Drugs; 1999; 31(1):53-7. PubMed ID: 10332639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual recovery among people with serious mental illnesses and substance problems: a qualitative analysis.
    Green CA; Yarborough MT; Polen MR; Janoff SL; Yarborough BJ
    J Dual Diagn; 2015; 11(1):33-41. PubMed ID: 25491440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders].
    Liraud F; Verdoux H
    Encephale; 2002; 28(2):160-8. PubMed ID: 11972143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychotic symptoms, self-harm and violence in individuals with schizophrenia and substance misuse problems.
    Haddock G; Eisner E; Davies G; Coupe N; Barrowclough C
    Schizophr Res; 2013 Dec; 151(1-3):215-20. PubMed ID: 24268935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics of cough mixture abusers referred to three substance abuse clinics in Hong Kong: a retrospective study.
    Tang AK; Tang WK; Liang HJ; Chan F; Mak SC; Ungvari GS
    East Asian Arch Psychiatry; 2012 Dec; 22(4):154-9. PubMed ID: 23271584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute behavioral crises in psychiatric inpatients with autism spectrum disorder (ASD): recognition of concomitant medical or non-ASD psychiatric conditions predicts enhanced improvement.
    Guinchat V; Cravero C; Diaz L; Périsse D; Xavier J; Amiet C; Gourfinkel-An I; Bodeau N; Wachtel L; Cohen D; Consoli A
    Res Dev Disabil; 2015 Mar; 38():242-55. PubMed ID: 25575287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achieving effective treatment of patients with chronic psychotic illness and comorbid substance dependence.
    Ho AP; Tsuang JW; Liberman RP; Wang R; Wilkins JN; Eckman TA; Shaner AL
    Am J Psychiatry; 1999 Nov; 156(11):1765-70. PubMed ID: 10553741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limiting inpatient substance use treatment: what are the consequences?
    Dickey B; Normand SL; Drake R; Weiss RD; Azeni H; Hanson A
    Med Care Res Rev; 2003 Sep; 60(3):332-46. PubMed ID: 12971232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dual diagnosis in psychiatric inpatients: prevalence and general characteristics].
    Rodríguez-Jiménez R; Aragüés M; Jiménez-Arriero MA; Ponce G; Muñoz A; Bagney A; Hoenicka J; Palomo T
    Invest Clin; 2008 Jun; 49(2):195-205. PubMed ID: 18717266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year follow-up of dual diagnosis patients attending a 4-month integrated inpatient treatment.
    Moggi F; Brodbeck J; Költzsch K; Hirsbrunner HP; Bachmann KM
    Eur Addict Res; 2002 Jan; 8(1):30-7. PubMed ID: 11818691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of schizophrenia with substance use disorders.
    Lybrand J; Caroff S
    Psychiatr Clin North Am; 2009 Dec; 32(4):821-33. PubMed ID: 19944886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of schizoaffective disorder. Are there any differences with respect to schizophrenia?
    Pinna F; Sanna L; Perra V; Pisu Randaccio R; Diana E; Carpiniello B;
    Riv Psichiatr; 2014; 49(1):41-9. PubMed ID: 24572583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substance use in a large sample of patients with schizophrenia or related disorders and co-morbid obsessive-compulsive symptoms.
    Dekker N; Swets M;
    Aust N Z J Psychiatry; 2013 Sep; 47(9):868-74. PubMed ID: 23723291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.